Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we report the discovery and characterization of a novel selective DGAT1 inhibitor 29 to potentially treat obesity.
|
29699923 |
2018 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans.
|
28498655 |
2017 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diacylglycerol acyltransferase-1 (DGAT1), a key enzyme in triglyceride (TG) biogenesis, is highly associated with metabolic abnormalities, such as obesity and type 2 diabetes.
|
26493024 |
2016 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These cases of DGAT1 deficiency extend the molecular and phenotypic spectrum of PLE, suggesting a re-evaluation of the use of DGAT1 inhibitors for metabolic disorders including obesity and diabetes.
|
26883093 |
2016 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dgat1(-/-) mice exhibit a number of beneficial metabolic effects including reduced obesity and improved insulin sensitivity and no known cardiac dysfunction.
|
25157099 |
2014 |
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Pre-existing maternal obesity and GDM are associated with decreased expression in genes involved in fatty acid uptake and intracellular transport (LPL, FATP2, FATP6, FABPpm and ASCL1), triacylglyceride (TAG) biosynthesis (MGAT1,7 MGAT2 and DGAT1), lipogenesis (FASN) and lipolysis (PNPLA2, HSL and MGLL).
|
24262292 |
2014 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Findings from genetically modified mice as well as pharmacological studies suggest that inhibition of DGAT1 is a promising strategy for the treatment of obesity and type 2 diabetes.
|
21990351 |
2011 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases.
|
18183944 |
2008 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that pharmacological inhibition of DGAT1 may be a feasible therapeutic strategy for human obesity and type 2 diabetes.
|
15569818 |
2005 |
Obesity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested whether augmentation of triglyceride synthesis in adipose tissue by transgenic overexpression of the diacylglycerol aclytransferase-1 (Dgat1) gene causes obesity and/or alters insulin sensitivity.
|
16306352 |
2005 |
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, DGAT1 deficiency protects against insulin resistance and obesity in agouti yellow mice, a model of severe leptin resistance.
|
11956242 |
2002 |